Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
NASDAQ:CYTK
Cytokinetics (CYTK) Ownership - Who Owns Cytokinetics?
976 Followers
Cytokinetics (CYTK) Ownership Overview
15.54% Insiders
35.63% Mutual Funds
23.51% Other Institutional Investors
25.32% Public Companies and
Individual Investors
The ownership structure of Cytokinetics (CYTK) stock is a mix of institutional, retail and individual investors. Approximately 59.14% of the company’s stock is owned by Institutional Investors, 15.54% is owned by Insiders and 25.32% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Jul 16, 2024 | Lynne Parshall Director | xxxxxxxxxxxxx | $279100 |
| Jul 10, 2024 | Robert Blum President & Ceo,director | xxxxxxxxxxxxx | $624335 |
| Jul 09, 2024 | Fady Ibraham Malik Evp Research & Development | xxxxxxxxxxxxx | $408103 |
| Jul 08, 2024 | Robert Arthur Harrington Director | xxxxxxxxxxxxx | $13816 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Mar 31, 2024 | xxxxxxxxxxxxx | $73615 | |
| Mar 31, 2024 | xxxxxxxxxxxxx | $232274 | |
| Mar 31, 2024 | xxxxxxxxxxxxx | $404114 | |
| Mar 31, 2024 | xxxxxxxxxxxxx | $985115 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 10,990,497 | Institution | 9.59% | 619,973,936 | |
| 9,732,337 | Institution | 8.49% | 549,001,130 | |
| 8,489,122 | Institution | 7.40% | 478,871,372 | |
| 4,512,602 | Institution | 3.94% | 254,555,879 | |
| 2,662,941 | Institution | 2.32% | 150,216,502 | |
| 2,341,721 | Institution | 2.04% | 132,096,482 | |
| 1,846,173 | Institution | 1.61% | 104,142,619 | |
| 1,530,371 | Institution | 1.33% | 86,328,228 | |
| 1,469,555 | Institution | 1.28% | 82,897,598 | |
| 1,325,083 | Institution | 1.16% | 74,747,932 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 8,489,122 | Institution | 7.40% | 478,871,372 | |
| 2,662,941 | Institution | 2.32% | 150,216,502 | |
| 2,341,721 | Institution | 2.04% | 132,096,482 | |
| 1,846,173 | Institution | 1.61% | 104,142,619 | |
| 1,530,371 | Institution | 1.33% | 86,328,228 | |
| 1,469,555 | Institution | 1.28% | 82,897,598 | |
| 1,325,083 | Institution | 1.16% | 74,747,932 | |
| 1,240,227 | Institution | 1.08% | 69,961,205 | |
| 1,108,230 | Institution | 0.97% | 62,515,254 | |
| 1,009,194 | Institution | 0.88% | 56,928,634 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 3,602,271 | Institution | 3.14% | 203,204,107 | |
| 3,619,985 | Institution | 3.16% | 196,130,787 | |
| 2,963,720 | Institution | 2.58% | 167,183,445 | |
| 2,882,134 | Institution | 2.51% | 156,154,020 | |
| 2,695,072 | Institution | 2.35% | 150,681,476 | |
| 1,746,330 | Institution | 1.52% | 94,616,159 | |
| 1,619,862 | Institution | 1.41% | 87,764,123 | |
| 946,167 | Institution | 0.83% | 53,373,280 | |
| 914,905 | Institution | 0.80% | 51,609,791 | |
| 788,999 | Institution | 0.69% | 44,507,434 |
FAQ
Who Owns Cytokinetics (CYTK)?
According to the latest TipRanks data, approximately 23.51% of the company's stock is held by institutional investors, 15.54% is held by insiders, and 25.32% is held by retail investors.
What percentage of Cytokinetics (CYTK) stock is held by institutional investors?
According to the latest TipRanks data, approximately 23.51% of Cytokinetics (CYTK) stock is held by institutional investors.
What percentage of Cytokinetics (CYTK) stock is held by retail investors?
According to the latest TipRanks data, approximately 25.32% of Cytokinetics (CYTK) stock is held by retail investors.
Who owns the most shares of Cytokinetics (CYTK)?
Vanguard owns the most shares of Cytokinetics (CYTK).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.